Induced pluripotent stem cell technology: Toward the future of cardiac arrhythmias

M. Gnecchi, M. Stefanello, M. Mura

Research output: Contribution to journalArticle

Abstract

The development of human induced pluripotent stem cell (iPSC) technology has revitalized the efforts made in the last decade to exploit the potential of human embryonic stem cells (ESCs) for scientific research. In the field of cardiac arrhythmias, the possibility of generating an unlimited amount of patient-specific cardiomyocyte-like cells (iPSC-CMs) has clear advantages compared with the use of ESC-derived cardiac cells. In particular, with the introduction and implementation of the large-scale precision medicine initiative, we anticipate that the iPSC technology will play an important role in the advancement of cardiovascular research and medicine. This platform is not free from technical limitations that must be carefully taken into account; however, the utility of iPSC-CMs in disease modeling and drug testing studies is hardly questionable. Here, we summarize some of the progresses made in the field of iPSC technology applied to inherited cardiac arrhythmias, with particular emphasis on the use of iPSC-CMs for modelling the long QT syndrome and for the development of personalized drug and molecular therapies. The growing role of iPSC technology in the practice of precision medicine will also be discussed.
Original languageEnglish
Pages (from-to)49-52
Number of pages4
JournalInternational Journal of Cardiology
Volume237
DOIs
Publication statusPublished - Jun 15 2017

Fingerprint

Induced Pluripotent Stem Cells
Cardiac Arrhythmias
Technology
Precision Medicine
Stem Cell Research
Long QT Syndrome
Drug Design
Embryonic Stem Cells
Cardiac Myocytes
Medicine
Drug Therapy
Research

Keywords

  • Arrhythmias
  • Heart disease
  • Induced pluripotent stem cells
  • Long QT syndrome
  • Modifier genes
  • Precision medicine

Cite this

Induced pluripotent stem cell technology: Toward the future of cardiac arrhythmias. / Gnecchi, M.; Stefanello, M.; Mura, M.

In: International Journal of Cardiology, Vol. 237, 15.06.2017, p. 49-52.

Research output: Contribution to journalArticle

@article{fe7b13cce39f4bcd9c56e5ec33114196,
title = "Induced pluripotent stem cell technology: Toward the future of cardiac arrhythmias",
abstract = "The development of human induced pluripotent stem cell (iPSC) technology has revitalized the efforts made in the last decade to exploit the potential of human embryonic stem cells (ESCs) for scientific research. In the field of cardiac arrhythmias, the possibility of generating an unlimited amount of patient-specific cardiomyocyte-like cells (iPSC-CMs) has clear advantages compared with the use of ESC-derived cardiac cells. In particular, with the introduction and implementation of the large-scale precision medicine initiative, we anticipate that the iPSC technology will play an important role in the advancement of cardiovascular research and medicine. This platform is not free from technical limitations that must be carefully taken into account; however, the utility of iPSC-CMs in disease modeling and drug testing studies is hardly questionable. Here, we summarize some of the progresses made in the field of iPSC technology applied to inherited cardiac arrhythmias, with particular emphasis on the use of iPSC-CMs for modelling the long QT syndrome and for the development of personalized drug and molecular therapies. The growing role of iPSC technology in the practice of precision medicine will also be discussed.",
keywords = "Arrhythmias, Heart disease, Induced pluripotent stem cells, Long QT syndrome, Modifier genes, Precision medicine",
author = "M. Gnecchi and M. Stefanello and M. Mura",
note = "LR: 20170523; CI: Copyright (c) 2017; JID: 8200291; OTO: NOTNLM; 2017/03/11 00:00 [received]; 2017/03/13 00:00 [accepted]; 2017/04/15 06:00 [pubmed]; 2017/04/15 06:00 [medline]; 2017/04/15 06:00 [entrez]; ppublish",
year = "2017",
month = "6",
day = "15",
doi = "S0167-5273(17)30862-8 [pii]",
language = "English",
volume = "237",
pages = "49--52",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Induced pluripotent stem cell technology: Toward the future of cardiac arrhythmias

AU - Gnecchi, M.

AU - Stefanello, M.

AU - Mura, M.

N1 - LR: 20170523; CI: Copyright (c) 2017; JID: 8200291; OTO: NOTNLM; 2017/03/11 00:00 [received]; 2017/03/13 00:00 [accepted]; 2017/04/15 06:00 [pubmed]; 2017/04/15 06:00 [medline]; 2017/04/15 06:00 [entrez]; ppublish

PY - 2017/6/15

Y1 - 2017/6/15

N2 - The development of human induced pluripotent stem cell (iPSC) technology has revitalized the efforts made in the last decade to exploit the potential of human embryonic stem cells (ESCs) for scientific research. In the field of cardiac arrhythmias, the possibility of generating an unlimited amount of patient-specific cardiomyocyte-like cells (iPSC-CMs) has clear advantages compared with the use of ESC-derived cardiac cells. In particular, with the introduction and implementation of the large-scale precision medicine initiative, we anticipate that the iPSC technology will play an important role in the advancement of cardiovascular research and medicine. This platform is not free from technical limitations that must be carefully taken into account; however, the utility of iPSC-CMs in disease modeling and drug testing studies is hardly questionable. Here, we summarize some of the progresses made in the field of iPSC technology applied to inherited cardiac arrhythmias, with particular emphasis on the use of iPSC-CMs for modelling the long QT syndrome and for the development of personalized drug and molecular therapies. The growing role of iPSC technology in the practice of precision medicine will also be discussed.

AB - The development of human induced pluripotent stem cell (iPSC) technology has revitalized the efforts made in the last decade to exploit the potential of human embryonic stem cells (ESCs) for scientific research. In the field of cardiac arrhythmias, the possibility of generating an unlimited amount of patient-specific cardiomyocyte-like cells (iPSC-CMs) has clear advantages compared with the use of ESC-derived cardiac cells. In particular, with the introduction and implementation of the large-scale precision medicine initiative, we anticipate that the iPSC technology will play an important role in the advancement of cardiovascular research and medicine. This platform is not free from technical limitations that must be carefully taken into account; however, the utility of iPSC-CMs in disease modeling and drug testing studies is hardly questionable. Here, we summarize some of the progresses made in the field of iPSC technology applied to inherited cardiac arrhythmias, with particular emphasis on the use of iPSC-CMs for modelling the long QT syndrome and for the development of personalized drug and molecular therapies. The growing role of iPSC technology in the practice of precision medicine will also be discussed.

KW - Arrhythmias

KW - Heart disease

KW - Induced pluripotent stem cells

KW - Long QT syndrome

KW - Modifier genes

KW - Precision medicine

U2 - S0167-5273(17)30862-8 [pii]

DO - S0167-5273(17)30862-8 [pii]

M3 - Article

VL - 237

SP - 49

EP - 52

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -